03-24492. New Animal Drugs; Change of Sponsor  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Final rule.

    SUMMARY:

    The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for two new animal drug applications (NADAs) and three abbreviated new animal drug applications (ANADAs) from Delmarva Pharmaceuticals, Inc., to Virbac AH, Inc.

    DATES:

    This rule is effective September 29, 2003.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    David R. Newkirk, Center for Veterinary Medicine (HFV-100), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-6967, e-mail: dnewkirk@cvm.fda.gov.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    Delmarva Laboratories, Inc., 1500 Huguenot Rd., suite 106, Midlothian, VA 23113, has informed FDA that it has transferred ownership of, and all rights and interest in, the following two approved NADAs and three approved ANADAs to Virbac AH, Inc., 3200 Meacham Blvd., Ft. Worth, TX 76137:

    Application No.21 CFR SectionTrade Name
    NADA 065-492520.88fROBAMOX V (amoxicillin trihydrate) Tablets
    NADA 065-495520.88bROBAMOX V (amoxicillin trihydrate)
    ANADA 200-071522.900EUTHASOL Solution
    ANADA 200-291520.447CLINSOL (clindamycin hydrochloride) Liquid
    ANADA 200-316520.446CLINTABS (clindamycin hydrochloride) Tablets
    Start Printed Page 55824

    Accordingly, the agency is amending the regulations in §§ 520.88b, 520.88f, 520.446, 520.447, and 522.900 to reflect the transfer of ownership.

    Following these changes of sponsorship, Delmarva Laboratories, Inc., is no longer the sponsor of an approved application. Accordingly, 21 CFR 510.600(c) is being amended to remove the entries for Delmarva Laboratories, Inc.

    This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

    Start List of Subjects

    List of Subjects

    21 CFR Part 510

    • Administrative practice and procedure
    • Animal drugs
    • Labeling
    • Reporting and recordkeeping requirements

    21 CFR Parts 520 and 522

    • Animal drugs
    End List of Subjects Start Amendment Part

    Therefore, under the Federal Food, Drug and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 520, and 522 are amended as follows:

    End Amendment Part Start Part

    PART 510—NEW ANIMAL DRUGS

    End Part Start Amendment Part

    1. The authority citation for 21 CFR part 510 continues to read as follows:

    End Amendment Part Start Authority

    Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

    End Authority
    [Amended]
    Start Amendment Part

    2. Section 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications is amended in the table in paragraph (c)(1) by removing the entry for “Delmarva Laboratories, Inc.” and in the table in paragraph (c)(2) by removing the entry for “059079”.

    End Amendment Part Start Part

    PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

    End Part Start Amendment Part

    3. The authority citation for 21 CFR part 520 continues to read as follows:

    End Amendment Part Start Authority

    Authority: 21 U.S.C. 360b.

    End Authority
    [Amended]
    Start Amendment Part

    4. Section 520.88b Amoxicillin trihydrate for oral suspension is amended in paragraph (c) by removing “059079” and by adding in its place “051311”.

    End Amendment Part
    [Amended]
    Start Amendment Part

    5. Section 520.88f Amoxicillin trihydrate tablets is amended in paragraph (b) by removing “059079” and by adding in its place “051311”.

    End Amendment Part
    [Amended]
    Start Amendment Part

    6. Section 520.446 Clindamycin capsules and tablets is amended in paragraph (b)(3) by removing “059079” and by adding in its place “051311”.

    End Amendment Part
    [Amended]
    Start Amendment Part

    7. Section 520.447 Clindamycin liquid is amended in paragraph (b)(2) by removing “059079” and by adding in its place “051311”.

    End Amendment Part Start Part

    PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

    End Part Start Amendment Part

    8. The authority citation for 21 CFR part 522 continues to read as follows:

    End Amendment Part Start Authority

    Authority: 21 U.S.C. 360b.

    End Authority
    [Amended]
    Start Amendment Part

    9. Section 522.900 Euthanasia solution is amended in paragraph (b)(1) by removing “059079” and by adding in its place “051311”.

    End Amendment Part Start Signature

    Dated: September 15, 2003.

    Steven D. Vaughn,

    Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

    End Signature End Supplemental Information

    [FR Doc. 03-24492 Filed 9-26-03; 8:45 am]

    BILLING CODE 4160-01-S

Document Information

Effective Date:
9/29/2003
Published:
09/29/2003
Department:
Food and Drug Administration
Entry Type:
Rule
Action:
Final rule.
Document Number:
03-24492
Dates:
This rule is effective September 29, 2003.
Pages:
55823-55824 (2 pages)
PDF File:
03-24492.pdf
CFR: (6)
21 CFR 510.600
21 CFR 520.446
21 CFR 520.447
21 CFR 522.900
21 CFR 520.88b
More ...